BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin WR, Yeh CT. GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. Int J Mol Sci 2020;21:E1491. [PMID: 32098271 DOI: 10.3390/ijms21041491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Chu Y, Fan T, Lai M, Yeh C. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells. Cell Death Dis 2022;13:956. [DOI: 10.1038/s41419-022-05419-y] [Reference Citation Analysis]
2 Hu Q, Tian T, Leng Y, Tang Y, Chen S, Lv Y, Liang J, Liu Y, Liu T, Shen L, Dong X. The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer. Cell Mol Biol Lett 2022;27:71. [PMID: 36058918 DOI: 10.1186/s11658-022-00378-w] [Reference Citation Analysis]
3 Lin N, Shih Y, Chiu K, Li P, Yang H, Lan W, Hsia S, Wang T, Shieh T. Association of rs9679162 Genetic Polymorphism and Aberrant Expression of Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) in Head and Neck Cancer. Cancers 2022;14:4217. [DOI: 10.3390/cancers14174217] [Reference Citation Analysis]
4 Zhou L, Wu H, Bai X, Min S, Zhang J, Li C. O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer. Pathol Oncol Res 2022;28:1610554. [DOI: 10.3389/pore.2022.1610554] [Reference Citation Analysis]
5 Gao F, Zheng G, Shi Z. RUNX3-Regulated GALNT6 Promotes the Migration and Invasion of Hepatocellular Carcinoma Cells by Mediating O-Glycosylation of MUC1. Disease Markers 2022;2022:1-11. [DOI: 10.1155/2022/2959846] [Reference Citation Analysis]
6 Polewko-klim A, Zhu S, Wu W, Xie Y, Cai N, Zhang K, Zhu Z, Qing T, Yuan Z, Xu K, Zhang T, Lu M, Ye W, Chen X, Suo C, Rudnicki WR. Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma. Front Genet 2022;13:844542. [DOI: 10.3389/fgene.2022.844542] [Reference Citation Analysis]
7 Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, Chang ML, Lin CL, Yeh CT. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int 2022. [PMID: 34982369 DOI: 10.1007/s12072-021-10283-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rosa-fernandes L, Oba-shinjo SM, Macedo-da-silva J, Marie SKN, Palmisano G. Aberrant Protein Glycosylation in Brain Cancers, with Emphasis on Glioblastoma. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-031-05460-0_4] [Reference Citation Analysis]
9 Wang Y, Wang C, Fu Z, Zhang S, Chen J. miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway. Cancer Cell Int 2021;21:618. [PMID: 34819077 DOI: 10.1186/s12935-021-02323-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Wang Y, Gan Q, Cai X, Chen Z, Liu Q, Bai Y. GALNT14 promotes cancer stem cell-like characteristics and metastasis of nasopharyngeal carcinoma cells through upregulating SOX4. Mol Cell Toxicol 2021. [DOI: 10.1007/s13273-021-00188-9] [Reference Citation Analysis]
11 Fernandez E, Ubillos L, Elgul N, Festari MF, Mazal D, Pritsch O, Alonso I, Osinaga E, Berois N. Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer. Cancers (Basel) 2021;13:5616. [PMID: 34830771 DOI: 10.3390/cancers13225616] [Reference Citation Analysis]
12 Li HW, Liu MB, Jiang X, Song T, Feng SX, Wu JY, Deng PF, Wang XY. GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway. Future Oncol 2021. [PMID: 34643088 DOI: 10.2217/fon-2021-0883] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
13 Brockhausen I, Argüeso P. Mucin-Type O-Glycans: Biosynthesis and Functions. Comprehensive Glycoscience 2021. [DOI: 10.1016/b978-0-12-819475-1.00033-x] [Reference Citation Analysis]
14 Marijan S, Markotić A, Mastelić A, Režić-Mužinić N, Pilkington LI, Reynisson J, Čulić VČ. Glycosphingolipid expression at breast cancer stem cells after novel thieno[2,3-b]pyridine anticancer compound treatment. Sci Rep 2020;10:11876. [PMID: 32680999 DOI: 10.1038/s41598-020-68516-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]